Ascendis Pharma A/S (ASND) 6-K Current report (foreign)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TOSECTION 13a-16 OR15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2017

Commission File Number:001-36815

Ascendis Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

Tuborg Boulevard 5

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F.

Form 20-F ☒                 Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7):  ☐

INCORPORATION BY REFERENCE

This report on Form6-K shall be deemed to be incorporated by reference into the registration statements on FormS-8 (Registration Numbers333-203040,333-210810,333-211512,333-213412,333-214843 and333-216883) and FormF-3 (Registration Numbers333-209336,333-211511 and333-216882) of Ascendis Pharma A/S (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

The Company has receivedFollow-up Scientific Advice from the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) indicating CHMP’s concurrence with the Company’s proposed development plan for TransCon Growth Hormone for pediatric growth hormone deficiency.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Ascendis Pharma A/S
Date: November 28, 2017		By:	/s/ Michael Wolff Jensen
		Michael Wolff Jensen
		Chairman and Senior Vice President, General Counsel